It is therefore suggested that the benefit of tamoxifen in breast cancer treatment and prevention results from the growth inhibition of occult ER-positive tumours, and that tamoxifen is unlikely to prevent the progression of ER-poor tumours, which is said to be associated with a less favourable prognosis (Fisher et al, 1998). Here, ESR1 is linked to breast cancer.